Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority to UY27171ApriorityCriticalpatent/UY27171A1/en
Publication of UY27171A1publicationCriticalpatent/UY27171A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Son inhibidores selectivos de MMP-13 pirimidinas bicíclicas de la fórmula I, o una sal farmacéuticamente aceptable de las mismas. Un compuesto de fórmula I, o una sal farmacéuticamente aceptable del mismo, es útil para tratar el cáncer o la artritisThey are selective inhibitors of bicyclic MMP-13 pyrimidines of the formula I, or a pharmaceutically acceptable salt thereof. A compound of formula I, or a pharmaceutically acceptable salt thereof, is useful for treating cancer or arthritis.
UY27171A2002-02-132002-02-13
BICYCLIC PYRIMIDINES AS MATRIX METALOPROTEINASE INHIBITORS
UY27171A1
(en)
compound, pharmaceutical composition, kit, article of manufacture, and methods of inhibiting dpp-iv, therapeutic, and treating a disease state, cancer, autoimmune disorders, a condition and HIV infection
Compounds derived from 1,3,4-thiadiazole spiro-condensed, inhibitors of ksp kinesin activity; pharmaceutical composition; and its use in the treatment of proliferative diseases such as cancer, hyperplasia, cardiac hypertrophy, autoimmune diseases, fungal disorders, arthritis, graft rejection, among others.